Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women

Ju-Qi Ma, Chun-Fen Guo, Ayshamgul Hasim
In: Clinical and Experimental Obstetrics & Gynecology · 2018 · vol. 45(3) , pp. 387–390 · doi:10.12891/ceog4098.2018 · W3140186987
article OA: bronze CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study found that the levonorgestrel-releasing intrauterine system significantly reduced menstrual blood loss and dysmenorrhea, while improving quality of life in perimenopausal women with adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This study evaluated the clinical efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) for menorrhagia, dysmenorrhea, and quality of life in 96 perimenopausal women diagnosed with adenomyosis. After insertion in the postmenstrual phase and follow-up at 1, 3, 6, 12, and 18 months, menstrual blood loss measured by PBAC decreased significantly and dysmenorrhea intensity measured by VAS declined continuously and significantly, with SF-36 scores indicating significant quality-of-life improvement. The study excluded cervical and endometrial lesions via Pap smear, transvaginal sonography, and endometrial biopsy, but the abstract does not specify a control group or randomization and focuses on clinical outcomes only. This paper is centrally about adenomyosis — it assesses LNG-IUS effects on heavy bleeding, pain, and quality of life in perimenopausal women with adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of menorrhagia, dysmenorrhea, and poor quality of life caused by adenomyosis in perimenopausal women. Materials and Methods: Ninety-six women with menorrhagia, dysmenorrhea, and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Excluded were cervical and endometrial lesions that underwent a Pap smear, transvaginal sonography, and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). The patients were followed up after one, three, six, 12, and after 18 months. The participations are asked to complete the short form 36 (SF- 36) health survey questionnaires. Results: The menstrual blood size was (60.287 ± 21.832) (41.186 ± 16.153), (30.988 ± 15.670), (19.238 ± 13.649), (16 ± 11.464) after treatment one, three, six, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 ± 33.775, p p Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea, and improve the quality of life in patients with adenomyosis from perimenopausal women.
Full text 2,615 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of menorrhagia, dysmenorrhea, and poor quality of life caused by adenomyosis in perimenopausal women. Materials and Methods: Ninety-six women with menorrhagia, dysmenorrhea, and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Excluded were cervical and endometrial lesions that underwent a Pap smear, transvaginal sonography, and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). The patients were followed up after one, three, six, 12, and after 18 months. The participations are asked to complete the short form 36 (SF- 36) health survey questionnaires. Results: The menstrual blood size was (60.287 ± 21.832) (41.186 ± 16.153), (30.988 ± 15.670), (19.238 ± 13.649), (16 ± 11.464) after treatment one, three, six, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 ± 33.775, p < 0.05). The VAS of dysmenorrheal dropped continuously and significantly from the baseline score of (74.968 ± 15.889) to (38.797 ± 16.781), (24.857 ± 16.595), (15.840 ± 14.305), (10.784 ± 13.593), and (8.196 ± 12.919), respectively, after treatment one, three, six, 12, and after 18 months of the LNG-IUS insertion (p < 0.05). The results of SF-36 Health Survey shown the quality of life was significantly improved. Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea, and improve the quality of life in patients with adenomyosis from perimenopausal women.

Keywords

- Levonorgestrel intrauterine system - Menorrhagia - Dysmenorrhea - Adenomyosis - Perimenopause - SF-36 Health Survey

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK